Cargando…

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab

BACKGROUND: Recent studies have shown that immune-related adverse events (irAEs) caused by immune checkpoint inhibitors were associated with clinical benefit in patients with melanoma or lung cancer. In advanced gastric cancer (AGC) patients, there have been few reports about the correlation between...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masuda, Ken, Shoji, Hirokazu, Nagashima, Kengo, Yamamoto, Shun, Ishikawa, Masashi, Imazeki, Hiroshi, Aoki, Masahiko, Miyamoto, Takahiro, Hirano, Hidekazu, Honma, Yoshitaka, Iwasa, Satoru, Okita, Natsuko, Takashima, Atsuo, Kato, Ken, Boku, Narikazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805586/ https://www.ncbi.nlm.nih.gov/pubmed/31638948 http://dx.doi.org/10.1186/s12885-019-6150-y

Ejemplares similares

Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer
por: Aoki, Masahiko, et al.
Publicado: (2019)

Progression patterns and site‐specific responses in advanced gastric cancer patients treated with nivolumab
por: Kadono, Toru, et al.
Publicado: (2023)

Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study
por: Ishikawa, Masashi, et al.
Publicado: (2021)

Case report: potential treatment of metastatic amphicrine carcinoma of the rectum with FOLFOXIRI chemotherapy
por: Tamura, Nobumasa, et al.
Publicado: (2020)

Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
por: Takamizawa, Shigemasa, et al.
Publicado: (2021)

Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer
por: Oshima, Kotoe, et al.
Publicado: (2022)

Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy
por: Honma, Yoshitaka, et al.
Publicado: (2019)

Esophageal Metastasis from Rectal Cancer Successfully Treated with Fluorouracil-Based Chemotherapy with Bevacizumab: A Case Report and Review of the Literature
por: Watanabe, Sho, et al.
Publicado: (2017)

Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection
por: Shoji, Hirokazu, et al.
Publicado: (2014)

Immune status at pre-treatment impacts on progression-free survival of metastatic colorectal cancer patients treated with first-line chemotherapy
por: Tada, Kohei, et al.
Publicado: (2015)

Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy for unresectable sinonasal undifferentiated carcinoma: Two cases of report
por: Watanabe, Sho, et al.
Publicado: (2019)

Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503)
por: Iwasa, Satoru, et al.
Publicado: (2020)

The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy
por: Shoji, Hirokazu, et al.
Publicado: (2017)

Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer
por: Takahashi, Naoki, et al.
Publicado: (2015)

Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies
por: Takahashi, Naoki, et al.
Publicado: (2016)

Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer
por: Takahashi, Naoki, et al.
Publicado: (2015)

Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer
por: Kudo-Saito, Chie, et al.
Publicado: (2022)

Relationship between cervical esophageal squamous cell carcinoma and human papilloma virus infection and gene mutations
por: Fukahori, Masaru, et al.
Publicado: (2021)

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer
por: Takahashi, Naoki, et al.
Publicado: (2014)

A Phase I study of pevonedistat plus capecitabine plus oxaliplatin in patients with advanced gastric cancer refractory to platinum (NCCH-1811)
por: Shoji, Hirokazu, et al.
Publicado: (2021)

A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2023)

Temporal dynamics from phosphoproteomics using endoscopic biopsy specimens provides new therapeutic targets in stage IV gastric cancer
por: Hirano, Hidekazu, et al.
Publicado: (2022)

Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma
por: Hayashi, Hidetoshi, et al.
Publicado: (2014)

Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan
por: Aoki, Masahiko, et al.
Publicado: (2022)

CD11b(+)CTLA4(+) myeloid cells are a key driver of tumor evasion in colorectal cancer
por: Imazeki, Hiroshi, et al.
Publicado: (2021)

Comprehensive characterization of the phosphoproteome of gastric cancer from endoscopic biopsy specimens
por: Abe, Yuichi, et al.
Publicado: (2020)

Prognostic factors associated with the transition in treatment methods for brain metastases from colorectal cancer
por: Imaizumi, Jun, et al.
Publicado: (2023)

Usefulness of an S-1 dosage formula: an exploratory analysis of randomized clinical trial (JCOG1001)
por: Kawakami, Takeshi, et al.
Publicado: (2022)

Prognostic factors of brain metastases from colorectal cancer
por: Imaizumi, Jun, et al.
Publicado: (2019)

Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer: APOLLO-11 study
por: Takahari, Daisuke, et al.
Publicado: (2023)

Comparison of model fit and discriminatory ability of M category as defined by the 7th and 8th editions of the tumor‐node‐metastasis classification of colorectal cancer and the 9th edition of the Japanese classification
por: Shida, Dai, et al.
Publicado: (2021)

Clinical outcomes of surgical and imatinib treatment for rectal gastrointestinal stromal tumours: retrospective cohort study
por: Tsukamoto, Shunsuke, et al.
Publicado: (2022)

Geriatric assessment and management with question prompt list using a web-based application for elderly patients with cancer (MAPLE) to communicate ageing-related concerns: J-SUPPORT 2101 study protocol for a multicentre, parallel group, randomised controlled trial
por: Matsuoka, Ayumu, et al.
Publicado: (2022)

Shorter survival in adolescent and young adult patients, compared to adult patients, with stage IV colorectal cancer in Japan
por: Shida, Dai, et al.
Publicado: (2018)

Nutritional and inflammatory measures predict survival of patients with stage IV colorectal cancer
por: Takamizawa, Yasuyuki, et al.
Publicado: (2020)

Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study
por: Kitadai, Rui, et al.
Publicado: (2021)

Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
por: Boku, Narikazu, et al.
Publicado: (2021)

Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol
por: Osumi, Hiroki, et al.
Publicado: (2022)

Refractory hypotension due to Nivolumab-induced adrenal insufficiency
por: Tsukizawa, Yoshiaki, et al.
Publicado: (2018)

Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study
por: Yamaguchi, Kensei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cacj797rq0gagraunhjprciq7e